ABT's Structural Heart, Rhythm Management and Neuromodulation businesses are likely to have driven its first-quarter 2025 ...

Abbott Laboratories (NYSE:ABT) is set to report its first-quarter earnings results on Wednesday, April 16th, before the ...

RBC Capital analyst Shagun Singh raised the firm’s price target on Abbott (ABT) to $140 from $135 and keeps an Outperform rating on the shares ...

With a key regulatory approval secured in Europe, Abbott Laboratories is joining the race to commercialize technology that ...

Abbott took "a deliberately very different development path ... for the waveform" behind its Volt PFA system, said Dr.

A leader in Abbott's Heart Failure division announced that the company named Dr. Finn Gustafsson as the unit's chief medical ...

While the pandemic caused some of Abbott's segments to balloon (diagnostics) and others to fall short (medical devices), conditions have largely normalized and Abbott's prospects will again rely ...

The iShares U.S. Medical Devices ETF (IHI) was launched on 05/01/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Medical Devices segment of ...

Abbott Laboratories' stock has surged 25% in eight months, outperforming peers on strong medical device growth and perhaps market rotation to names with less perceived macro and geopolitical risk.

Pharmaceuticals were mostly spared on "Liberation Day," while medical devices were not, though the long-term impacts for both industries are far from clear. As President Donald Trump's executive order ...

Abbott Laboratories' second-generation pulse field ablation device for atrial fibrillation ... efficient," Dr. Christopher Piorkowski, chief medical officer of Abbott's electrophysiology business ...